Q4 2024 10X Genomics Inc Earnings Call Transcript
Key Points
- 10x Genomics Inc (TXG) launched major new products across all three platforms, receiving a tremendous customer response.
- The company introduced new products in the single-cell portfolio, offering lower prices per cell and sample, aiming to increase volumes over time.
- Spatial platform revenue grew by 33% year over year, driven by new product launches like Visium HD and Xenium Prime 5K.
- The company reorganized its sales force to better support its diverse product portfolio and customer base, aiming for full implementation by mid-2025.
- 10x Genomics Inc (TXG) is focusing on expanding its biopharma segment, which currently makes up 15-20% of revenue, with plans to grow it to 50% in the future.
- Total revenue for 2024 was $611 million, down 1% compared to the prior year, reflecting a challenging macro environment.
- Chromium consumables revenue decreased by 17% due to lower reaction prices, impacting overall revenue.
- Total instrument revenue decreased by 37%, with spatial instrument revenue down 51% due to fewer Xenium instruments sold.
- The company faces uncertainty regarding NIH funding, which constitutes 20-25% of its revenue, with potential impacts from indirect cost caps.
- 10x Genomics Inc (TXG) anticipates some lingering impact from commercial changes during the first half of 2025, particularly in the Xenium team.
Thank you for standing by. My name is Stella, and I will be your conference operator today. At this time, I would like to welcome everyone to the 10X Genomics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). I would now like to turn the conference over to Cassie Corneau, Senior Director of Investor Relations and Strategic Finance. You may begin.
Thank you and good afternoon, everyone. Earlier today, 10X Genomics released financial results for the fourth quarter and full year ended December 31, 2024. If you have not received this news release or if you would like to be added to the company's distribution list, please send an email to investors at 10xgenomics.com. An archived webcast of this call will be available on the investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call.
Before we begin, I'd like to remind you that management will make statements during this call that are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
